Exploring SLAMF6 as a Novel Target in Cancer Immunotherapy
Time: 11:15 am
day: Conference Day One
Details:
- Revealing SLAMF6 upregulation in cancer models as a new immune escape mechanism, advancing our understanding of tumour immune evasion
- Demonstrating SLAMF6 modulation in preclinical models and its critical role in protecting cancer cells from T cell-mediated killing
- Disrupting the SLAMF6 interaction in tumour models with Lead Biologics’ candidate antibody LB-116, triggering a potent anti-cancer immune response and informing therapeutic strategies
